A Single-center, Randomized, Placebo-controlled, Double-blind, Single-dose, Efficacy of PRF-108 4% and PRF-110 4% Versus Ropivacaine Solution 0.5% in an Experimental Pain Model
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2013
At a glance
- Drugs Ropivacaine (Primary)
- Indications Pain
- Focus Therapeutic Use
- 14 Apr 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 14 Apr 2011 Actual initiation date (Oct 2010) added as reported by ClinicalTrials.gov.
- 14 Apr 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.